increasing antimicrobial resistance ( Figure 1 , Table 1 ). Cultures grew E. coli, Enterobacter cloacae, Citrobacter amalonaticus, Proteus vulgaris, Enterococcus faecium, Providencia rettgeri, Morganella morganii, ESBL K. pneumoniae, and ESBL K. oxytoca. Antibiotics used to treat these isolates included nitrofurantoin, cephalexin, cefuroxime, ceftriaxone, levofloxacin, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, fosfomycin, piperacillin-tazobactam, meropenem, and ertapenem.
Across 20 presentations from November 2013 to October 2015, symptoms included urinary urgency and worsened incontinence 11 times, generalized fatigue (without urgency or incontinence) 5 times, both sets of symptoms 3 times, and dysuria with suprapubic tenderness once. Though her symptoms were somewhat atypical of cystitis, she was treated for urinary infection given significant pyuria on urinalyses, neurologic changes, and limited ability to review systems with her comorbidities. Symptoms prompted each urinalysis and urine culture, and all antibiotics were prescribed according to susceptibility results. No antibiotics were prescribed without symptoms and a positive urine culture. Except for 2 doses of fosfomycin, which she could not obtain, and 1 course of levofloxacin interrupted for rash, all antibiotic courses were completed. Extensive nonantibiotic UTI prevention was attempted from 2010 to 2014, including solifenacin succinate, vaginal estrogen, increased fluid intake, scheduled voiding, stool softeners, methenamine hippurate, and vitamin C.
In March 2015, she developed diarrhea, tested positive for C. difficile, and completed 16 days of metronidazole. The following 6 months, her symptomatic UTIs (with bacteriuria and pyuria) continued but with decreased symptom-free intervals between infections from weeks to days. After episodes with MDR K. oxytoca and K. pneumoniae were treated with intravenous ertapenem, a surgical port was placed in anticipation of further parenteral therapy.
In May 2015, a C. difficile relapse was treated with oral vancomycin with prolonged taper. After another C. difficile relapse in October, fecal microbiota transplantation (FMT) was planned. Antibiotics were discontinued 48 hours prior. Stool from an unrelated donor who underwent routine serological and stool testing was delivered via colonoscopy without complications. Nine days post-FMT, she had complete resolution of all UTI and Clostridium difficile infection (CDI) symptoms. At 25 months post-FMT, there have been no recurrences. Of 2 urinalyses obtained since FMT for symptoms of increased fatigue, neither has indicated bacteriuria or pyuria, and she has not been prescribed antibiotics.
DISCUSSION
FMT is safe and effective for recurrent CDI [1] . It has also emerged as potential therapy for decolonization of MDR organisms (MDROs), offering a safe and possibly cost-effective strategy for tackling antibiotic resistance beyond current efforts to improve antibiotic stewardship and prevent infection [2] .
Intestinal MDRO decolonization after FMT has been described in case reports, retrospective studies, and a prospective single-center study [3] [4] [5] . However, MDRO eradication from nongastrointestinal body sites is not as well described [6] . A recent review found that FMT for recurrent Clostridium difficile infection (RCDI) was associated with decreased UTI frequency and improved antibiotic susceptibility profiles [7] . Case reports have also described interruption of recurrent UTIs with a Verona integron-encoded metallo-β-lactamase-positive MDR P. aeruginosa, recurrent renal allograft pyelonephritis with ESBL E. coli, and carbapenemase-producing K. pneumoniae osteomyelitis and sepsis [8] [9] [10] .
Here, we describe resolution of recurrent symptomatic UTI after FMT for RCDI in a woman who had been treated with nearly continuous antibiotics in the preceding 2 years. As common sources of morbidity, UTIs make significant contributions toward antibiotic resistance and antibiotic-associated infections. Though FMT may have changed provider behavior, post-FMT urine cultures were not indicated in the absence of further symptoms. Pre-or post-FMT stool cultures were not obtained for microbiota analysis. However, our case adds evidence for FMT as a safe and potentially efficacious intervention for the prevention and treatment of infections outside of C. difficile, suggesting a possible role for FMT in combatting antimicrobial resistance. 
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